ArticleThe Journal of experimental medicine2005
The Pim kinases control rapamycin-resistant T cell survival and activation.
Article in The Journal of experimental medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 183 citations in OpenAlex.
- Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study.Leukemia & lymphoma · 2008Trial
- Therapeutic Immune Reprogramming by Rapamycin Attenuates Plaque Inflammation and Lymphoid Immune Responses in Aged Atherosclerotic Mice.Aging cell · 2026Article
- Progressive deterioration of adaptive immune repertoires in Down syndrome linked to interferon hyperactivity and lymphoid tissue disorganization.bioRxiv : the preprint server for biology · 2026Article
- Targeting PIM2 improves antitumor immunity through promoting effector function and persistence of CD8 T cells.The Journal of clinical investigation · 2026Article
- Spatial Imbalance of Innate-like T-Cell Niches Underlies Clinical Trajectories in Psoriasis.International journal of molecular sciences · 2026Article
- Article
- Inhibition of PIM Kinase in Tumor-Associated Macrophages Suppresses Inflammasome Activation and Sensitizes Prostate Cancer to Immunotherapy.Cancer immunology research · 2025Article
- Review
- Molecular and cellular immune features of aged patients with severe COVID-19 pneumonia.Communications biology · 2022Article
- Targeting PIM1-Mediated Metabolism in Myeloid Suppressor Cells to Treat Cancer.Cancer immunology research · 2021Article
- PIM2 promotes hepatocellular carcinoma tumorigenesis and progression through activating NF-κB signaling pathway.Cell death & disease · 2020Article
- Pim-1 Protects Retinal Ganglion Cells by Enhancing Their Regenerative Ability Following Optic Nerve Crush.Experimental neurobiology · 2020Article
- Efficient Access to 3,5-Disubstituted 7-(Trifluoromethyl)pyrazolo[1,5-Molecules (Basel, Switzerland) · 2020Article
- FoxP3 in TClinical and experimental immunology · 2020Review
- The role of Pim kinase in immunomodulation.American journal of cancer research · 2020Review
- mTOR Signaling pathway as a master regulator of memory CD8Journal of cellular physiology · 2019Review
- Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Foxp3 Post-translational Modifications and Treg Suppressive Activity.Frontiers in immunology · 2019Review
- Forkhead box transcription factors as context-dependent regulators of lymphocyte homeostasis.Nature reviews. Immunology · 2018Review
- PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity.The Journal of clinical investigation · 2018Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although Pim-1 or Pim-2 can contribute to lymphoid transformation when overexpressed, the physiologic role of these kinases in the immune response is uncertain. We now report that T cells from Pim-1(-/-)Pim-2(-/-) animals display an unexpected sensitivity to the immunosuppressant rapamycin. Cytokine-induced Pim-1 and Pim-2 promote the rapamycin-resistant survival of lymphocytes. The endogenous function of the Pim kinases was not restricted to the regulation of cell survival. Like the rapamycin target TOR, the Pim kinases also contribute to the regulation of lymphocyte growth and proliferation. Although rapamycin has a minimal effect on wild-type T cell expansion in vitro and in vivo, it completely suppresses the response of Pim-1(-/-)Pim-2(-/-) cells. Thus, endogenous levels of the Pim kinases are required for T cells to mount an immune response in the presence of rapamycin. The existence of a rapamycin-insensitive pathway that regulates T cell growth and survival has important implications for understanding how rapamycin functions as an immunomodulatory drug and for the development of complementary immunotherapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.